Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTL001 (ProCervix) + Imiquimod in HPV 16/18 Infected Women
NCT02689726Phase 1Terminated
- Sponsor
- Genticel
- Start
- Aug 2015
- Primary completion
- Aug 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GTL001 in human papillomavirus infection, sponsored by Genticel. Primary endpoint: Incidence of local and systemic reactions. Started Aug 2015; status: terminated.
02
Drugs
GTL001
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT02689726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689726.